Rheumatology

Spondyloarthritis

Looking Ahead to ACR Convergence 2026: The Topics Our Experts Are Excited About

conference reporter by Marina N. Magrey, MD; Philip J. Mease, MD, MACR

Overview

As the Spondyloarthritis community prepares to gather for ACR Convergence 2026, anticipation is building around the latest developments in treatment, diagnostics, clinical research, and patient care. Ahead of this year’s meeting, we asked our Expert panel to share what they are most eager to follow and the developments they believe could have the greatest impact.

“With regard to spondyloarthritis, what I am most excited to follow at ACR Convergence 2026 are the new 2026 ACR/SPARTAN/SAA guidelines for the treatment of axial spondyloarthritis as well as the new definition of MRI indicative of axial spondyloarthritis in the sacroiliac joints, which is supported by data-driven and consensus-based recommendations by SPARTAN and the Society of Skeletal Radiology.”

— Marina N. Magrey, MD

Stay tuned for continued coverage from ACR Convergence 2026, where our Conference Reporter Expert panel will share key takeaways, emerging data, and expert perspectives throughout the meeting as part of our Conference Reporter^® in Spondyloarthritis series.

This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the American College of Rheumatology.

Profile

Marina N. Magrey, MD

Roland Moskowitz, Professor of Rheumatology
Case Western Reserve University School of Medicine
Chief, Division of Rheumatology
Director, Spondyloarthritis Center
University Hospitals Cleveland Medical Center
Cleveland, OH

Profile

Philip J. Mease, MD, MACR

Director of Rheumatology Research
Providence Swedish Medical Center
Clinical Professor
University of Washington School of Medicine
Seattle, WA